Proteomics International signs deal to launch PromarkerD test for diabetic kidney disease in USA

Proteomics International Ltd (Proteomics International; ASX: PIQ) has signed the first licence agreement for its world-leading PromarkerD predictive test for diabetic kidney disease in the United States, creating a partnership with US-based precision medicine and diagnostic services laboratory PrismHealthDx, Inc. (PHDx).

Media release


  • This field is for validation purposes and should be left unchanged.